Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland

References

• Ah, Y. M., Suh, Y., Jun, K., Hwang, S., & Lee, J. Y. (2019). Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: A population-based study. Basic & Clinical Pharmacology & Toxicology, 124(6), 741–748. doi:10.1111/bcpt.13184
   PubMed Web of Science ®Google Scholar
• Barry, H. E., Cooper, J. A., Ryan, C., Passmore, A. P., Robinson, A. L., Molloy, G. J., … Hughes, C. M. (2016). Potentially inappropriate prescribing among people with dementia in primary care: A retrospective cross-sectional study using the enhanced prescribing database. Journal of Alzheimer's Disease, 52(4), 1503–1513. doi:10.3233/JAD-151177
   PubMed Web of Science ®Google Scholar
• Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of anticholinergics on the aging brain: A review and practical application. Aging Health, 4(3), 311–320. (Vol. Issue doi:10.2217/1745509X.4.3.311
   Google Scholar
• Carnahan, R. M., Lund, B. C., Perry, P. J., & Chrischilles, E. A. (2004). The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? Journal of the American Geriatrics Society, 52(12), 2082–2087. doi:10.1111/j.1532-5415.2004.52563.x
   PubMed Web of Science ®Google Scholar
• Chatterjee, S., Bali, V., Carnahan, R. M., Johnson, M. L., Chen, H., & Aparasu, R. R. (2016). Anticholinergic medication use and risk of dementia among elderly nursing home residents with depression. The American Journal of Geriatric Psychiatry : official Journal of the American Association for Geriatric Psychiatry, 24(6), 485–495. doi:10.1016/j.jagp.2015.12.011
   PubMed Web of Science ®Google Scholar
• Cooper, C., Lodwick, R., Walters, K., Raine, R., Manthorpe, J., Iliffe, S., & Petersen, I. (2016). Observational cohort study: Deprivation and access to anti-dementia drugs in the UK. Age and Ageing, 45(1), 148–154. doi:10.1093/ageing/afv154
   PubMed Web of Science ®Google Scholar
• Corbett, A., Burns, A., & Ballard, C. (2014). Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. Bmj, 349, g6420.
   Google Scholar
• Cross, A. J., George, J., Woodward, M. C., Ames, D., Brodaty, H., Wolfe, R., … Elliott, R. A. (2017). Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics. Journal of Alzheimer's Disease, 60(2), 349–358. doi:10.3233/JAD-170265
   PubMed Web of Science ®Google Scholar
• Department of Health Social Services and Public Safety Northern Ireland (2011). Improving Dementia Services in Northern Ireland. November 2011. http://www.dhsspsni.gov.uk/improving-dementia-services-in-northern-ireland-a-regional-strategy-november-2011.pdf.
   Google Scholar
• Durán, C. E., Azermai, M., & Vander Stichele, R. H. (2013). Systematic review of anticholinergic risk scales in older adults. European Journal of Clinical Pharmacology, 69(7), 1485–1496. doi:10.1007/s00228-013-1499-3
   PubMed Web of Science ®Google Scholar
• Dyer, A. H., Murphy, C., Segurado, R., Lawlor, B., & Kennelly, S. P, for the NILVAD Study Group (2020). Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer’s disease? The Journals of Gerontology: Series A, 75(5), 987–994. doi:10.1093/gerona/glz244
   PubMed Web of Science ®Google Scholar
• Fox, C., Livingston, G., Maidment, I. D., Coulton, S., Smithard, D. G., Boustani, M., & Katona, C. (2011). The impact of anticholinergic burden in Alzheimer’s dementia-the laser-AD study. Age and Ageing, 40(6), 730–735. doi:10.1093/ageing/afr102
   PubMed Web of Science ®Google Scholar
• Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., Matthews, F. E., Smithard, D., … Brayne, C. (2011). Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study. Journal of the American Geriatrics Society, 59(8), 1477–1483. doi:10.1111/j.1532-5415.2011.03491.x
   PubMed Web of Science ®Google Scholar
• Fox, C., Smith, T., Maidment, I., Hebding, J., Madzima, T., Cheater, F., … Young, J. (2014). The importance of detecting and managing comorbidities in people with dementia? Age and Ageing, 43(6), 741–743. doi:10.1093/ageing/afu101
   PubMed Web of Science ®Google Scholar
• Garcia-Ptacek, S., Farahmand, B., Kåreholt, I., Religa, D., Cuadrado, M. L., & Eriksdotter, M. (2014). Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. Journal of Alzheimer's Disease, 41(2), 467–477. doi:10.3233/JAD-131856
   PubMed Web of Science ®Google Scholar
• Gray, S. L., & Hanlon, J. T. (2016). Anticholinergic medication use and dementia: Latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 7(5), 217–224. doi:10.1177/2042098616658399
   PubMedGoogle Scholar
• Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., … Larson, E. B. (2015). Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Internal Medicine, 175(3), 401–407. doi:10.1001/jamainternmed.2014.7663
   PubMed Web of Science ®Google Scholar
• Guthrie, B., Clark, S. A., & Mccowan, C. (2010). The burden of psychotropic drug prescribingin people with dementia: a populationdatabase study. Age and Ageing, 39(5), 637–642. doi:10.1093/ageing/afq090
   PubMed Web of Science ®Google Scholar
• Howland, R. H. (2009). Medication holidays. Journal of Psychosocial Nursing and Mental Health Services, 47(9), 15–18. doi:10.3928/02793695-20090804-01
   Web of Science ®Google Scholar
• Hox, J. J., Moerbeek, M., & Schoot, R. V. (2018). Multilevel analysis: Techniques and applications. New York: Routledge Taylor & Francis Group.
   Google Scholar
• Joung, K., Kim, S., Cho, Y. H., & Cho, S. (2019). Association of anticholinergic use with incidence of Alzheimer’s disease: Population-based cohort study. Scientific Reports, 9(1), 6802. doi:10.1038/s41598-019-43066-0
   PubMedGoogle Scholar
• Karimi, S., Dharia, S., Flora, D., & Slattum, P. (2012). Anticholinergic burden: Clinical implications for seniors and strategies for clinicians. The Consultant Pharmacist®, 27(8), 564–582. doi:10.4140/TCP.n.2012.564
   PubMedGoogle Scholar
• McMichael, A. J., Zafeiridi, E., & McGuinness, B. (2020). Do anticholinergic drugs influence cognition: Data from wave 1 of the NICOLA study. Manchester, UK: British and Irish Longitudinal Studies.
   Google Scholar
• McMichael, A. J., Zafeiridi, E., Passmore, P., Cunningham, E. L., & McGuinness, B. (2020). Factors associated with mortality including nursing home transitions: A retrospective analysis of 25,418 people prescribed anti-dementia drugs in Northern Ireland. Journal of Alzheimer's Disease, 73(3), 1233–1242. doi:10.3233/JAD-190751
   PubMed Web of Science ®Google Scholar
• Northern Ireland Statistics and Research Agency (2010). Northern Ireland Multiple Deprivation Measure 2017 (NIMDM2017) | Northern Ireland Statistics and Research Agency. Retrieved August 27, 2018, from https://www.nisra.gov.uk/statistics/deprivation/northern-ireland-multiple-deprivation-measure-2017-nimdm2017.
   Google Scholar
• O’reilly, D., Rosato, M., Catney, G., Johnston, F., & Brolly, M. (2012). Cohort description: The Northern Ireland longitudinal study (NILS). International Journal of Epidemiology, 41(3), 634–641.
   PubMed Web of Science ®Google Scholar
• Palmer, J. B., Albrecht, J. S., Park, Y., Dutcher, S., Rattinger, G. B., Simoni-Wastila, L., … Zuckerman, I. H. (2015). Use of drugs with anticholinergic properties among nursing home residents with dementia: A national analysis of medicare beneficiaries from 2007 to 2008. Drugs & Aging, 32(1), 79–86. doi:10.1007/s40266-014-0227-8
   PubMed Web of Science ®Google Scholar
• Salahudeen, M. S., Chyou, T. Y., & Nishtala, P. S. (2016). Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: A systematic review and meta-analysis of the literature. PLoS One, 11(3), e0151084. doi:10.1371/journal.pone.0151084
   PubMed Web of Science ®Google Scholar
• Salahudeen, M. S., Hilmer, S. N., & Nishtala, P. S. (2015). Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. Journal of the American Geriatrics Society, 63(1), 85–90. doi:10.1111/jgs.13206
   PubMed Web of Science ®Google Scholar
• Schneider, L. S., Dagerman, K., & Insel, P. S. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 14(3), 191–210. doi:10.1097/01.JGP.0000200589.01396.6d
   PubMed Web of Science ®Google Scholar
• Schulze, J., van den Bussche, H., Glaeske, G., Kaduszkiewicz, H., Wiese, B., & Hoffmann, F. (2013). Impact of safety warnings on antipsychotic prescriptions in dementia: Nothing has changed but the years and the substances. European Neuropsychopharmacology, 23(9), 1034–1042. doi:10.1016/j.euroneuro.2013.02.001
   PubMed Web of Science ®Google Scholar
• Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., … Martin, J. H. (2015). Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Internal Medicine, 175(5), 827–834. doi:10.1001/jamainternmed.2015.0324
   PubMed Web of Science ®Google Scholar
• Tan, E. C., Eriksdotter, M., Garcia-Ptacek, S., Fastbom, J., & Johnell, K. (2018). Anticholinergic burden and risk of stroke and death in people with different types of dementia. Journal of Alzheimer's Disease, 65(2), 589–596.
   Google Scholar
• van de Vorst, I. E., Koek, H. L., Stein, C. E., Bots, M. L., & Vaartjes, I. (2016). Socioeconomic disparities and mortality after a diagnosis of dementia: Results from a nationwide registry linkage study. American Journal of Epidemiology, 184(3), 219–226. doi:10.1093/aje/kwv319
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2012). Dementia: A public health priority. Dementia, 112https://doi.org/9789241564458
   Google Scholar